TITLE:
Viral Hepatitis B under Tenofovir in Ouagadougou (Burkina Faso)
AUTHORS:
Soudré Sandrine Marie-Odile Bobilwindé, Napon Fahosiata, Zoungrana Steve Léonce, Ouattara Zanga Damien, Koura Mali, Guingané Nanelin Alice, Somda Sosthène, Coulibaly Aboubacar, Beni Da Nathalie, Salou Rodrigue, Bougouma Alain, Sombié Arsène Roger
KEYWORDS:
Viral Hepatitis B, Tenofovir, Compliance, Tolerance, Efficacy
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.11 No.8,
August
27,
2021
ABSTRACT: Introduction: The treatment of viral hepatitis B is based on nucleotide analogs(s).
In Burkina Faso, tenofovir is the most widely used because of its effectiveness
and cost. The aim of this study was to describe viral hepatitis B under
tenofovir in Ouagadougou. Material and Method: This was a longitudinal study,
carried out in the outpatient department of the University Hospital of
Tengandogo from May 1, 2013 to September 31, 2020, i.e. a period of seven (07) years and five (05) months. All
patients with chronic hepatitis B virus who had been taking tenofovir for at
least one year were included in the study. Cases of hepatocellular carcinoma
and co-infections with hepatitis D, C and human immunodeficiency viruses were
excluded from the study. Results: Of 321 patients with hepatitis B, 120
were on tenofovir and 34 were included in our study. These were 24 men and 10
women with an average age of 39 years. Hepatitis B was most often discovered
following systematic or voluntary screening (44.1%) or pain in the right
hypochondrium (23.5%). The mean initial viral load was 7.9 log.
Ten patients had moderate compliance and four were non-compliant. No side
effects were reported in 91.3% of cases. The virologic response was complete in
72.7% of patients after six months. Nine out of ten patients showed a
biochemical response after 16 months. A histological response was observed in
19/27 patients within a mean of 26.7 months. HBs seroconversion was found in
2/24 patients. Conclusion: Tenofovir is effective in the treatment of
viral hepatitis B, but HBs seroconversion is rarely achieved.